References: Gallbladder Cancer

 

Abou-Alfa GK, Jarnagin W, Lowery M, D’Angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O’Reilly EM. Liver and bile duct cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1373-1395.

American Cancer Society. Cancer Facts & Figures 2018. Atlanta, Ga: American Cancer Society; 2018.

American Joint Committee on Cancer.  AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 201-205; 303-309.

Blair AB, Murphy A. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer. 2017 Oct [Epub ahead of print].

Castro CM, Santibanez SP, Rivas TC, Casses NJ. Totally laparoscopic radical resection of gallbladder cancer: Technical aspects and long-term results. World J Surg. 2018 Mar [Epub ahead of print].

DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018; 14(6):553-566.

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.

Kim TG. Patterns of initial failure after resection for gallbladder cancer: Implications for adjuvant radiotherapy. Radiat Oncol J. 2017; 35(4):359-367.

Koca YS, Bulbul M, Barut I. The diagnostic roles of cytokines in hepatobiliary cancer. BioMed Res Inter. 2017; 2017(ID2979307):1-5.

Koshiol J, Gao Y-T, Corbel A, Kemp TJ, Shen M-C, Hildesheim A, Hsing AW, Rashid A, Wang B, Pfeiffer RM, Pinto LA. Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high risk regions. Cancer Epidemiology. 2018; 54:25-30.

Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67.

Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY. The correlation between serum chemokines and clinical outcome in patients with advanced biliary tract cancer. Translational Oncology. 2018; 11:353-357.

Lombardi P, Marino D, Fenocchio E, Chila, G, Aglietta M, Leone F. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs. 2018 Feb;23(1):63-75.

National Cancer Institute. Physician Data Query (PDQ). Gallbladder Cancer Treatment. 01/25/2018. Accessed at https://www.cancer.gov/types/gallbladder/hp/gallbladder-treatment-pdq on March 29, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. v.1.2018. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf on March 29, 2018.

Patel T, Borad MJ. Carcinoma of the biliary tree. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2015:715-735.

Ratanaprasatporn L, Uyeda JW, Wortman JR, Richardson I, Sodickson AD. Multimodality imaging, including dual-energy CT, in the evaluation of gallbladder disease. RadioGraphics. 2018; 38:75-89.

Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya K S, Schwartz AL, Bandera E V, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA: A Cancer Journal for Clinicians. 2012 Jul-Aug;62(4):242–274.

Shukla SK, Singh G, Shahi KS, Bhuvan, Pant P. Staging, treatment, and future approaches of gallbladder carcinoma. J of Gastrointest Ca. 2018; 49:9-15.

Ye Y-Y, Mei J-W, Xiang S-S, Li H-F, Ma QQ…..Liu Y-B. MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. Cell Death and Disease. 2018; 9:410.

Zaidi MY, Maithel SK. Updates on gallbladder cancer management. Current Oncology Reports. 2018; 20(21):1-7 [Epub ahead of print]. 

Zhang L, Hou C, Xu Z, Wang L, Ling X, Xiu D. Laparoscopic treatment for suspected gallbladder cancer confined to the wall: A 10 year study from a single institution. Chinese Journal of Cancer Research. 2018; 30(1):84-92.

Zhu J-Q, Han D-D, Li X-L, K J-T, Fan H, He Q. Predictors of incidental gallbladder cancer in elderly patients. Hepatobiliary Pancreat Dis Int. 2015; 14:96-100.

 

 

 

 

Abou-Alfa GK, Jarnagin W, Lowery M, et al. Chapter 80: Liver and bile duct cancer. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society; 2016.

American Cancer Society. Cancer Facts & Figures 2017. Atlanta, Ga: American Cancer Society; 2017.

American Joint Committee on Cancer. Gallbladder. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010: 211-214.

Bartlett DL, Ramanathan RK, Ben-Josef E. Cancer of the biliary tree. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: 1019-1047.

Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013;11:28-34.

Dixon E, Vollmer CM, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer. Ann Surgery. 2005;241:385-394.

Fong Y, Wagman L, Gonen M, et al. Evidence-based gallbladder cancer staging: Changing cancer staging by analysis of data from the National Cancer Database. Ann Surg. 2006;243:767-771.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Lazcano-Ponce EC, Miquesl JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349-364.

Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: Evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007;31(6):907-913.

Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncology. 2003;4:167-176.

National Cancer Institute. Physician Data Query (PDQ). Gallbladder Cancer Treatment. 2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/gallbladder/HealthProfessional on September 4, 2014.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V.2.2014. Accessed at www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf on September 4, 2014.

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-1281.

Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumor. Nature Reviews Cancer. 2004;4:695-706.